Halaven(TM) (Eribulin) Receives European Commission Approval For Advanced Breast Canc

[News]

Eisai announced today that it has received approval from the European Commission for Halaven(TM) (Eribulin) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease...

More... (http://www.medicalnewstoday.com/articles/219938.php)